Skip to content
Buy This GLP
← Research
Evidence

Can You Take a GLP-1 If You Have Had Pancreatitis? What Records Show

Studies based on medical records disagree on pancreatitis recurrence. Wegovy and Zepbound prescribing information tells clinicians to stop treatment if pancreatitis is suspected.

Editorial profile: Neil SandersBuy This GLP Editorial Team5 min read
Acute pancreatitis recurrence after a prior episodeon a GLP-113.8%not on one40.9%Records study subgroup without other recorded risk factors.A separate cohort found a higher hazard in a different population.

What the Wegovy and Zepbound labels say

The prescribing information warns that acute pancreatitis has occurred with GLP-1 treatment. While reviewing GLP-1 side effects, pay particular attention to persistent or severe abdominal pain, which can spread to the back and may occur with or without nausea or vomiting. If you develop symptoms suggestive of pancreatitis while taking Wegovy or Zepbound, stop the medication and seek medical care promptly, as directed in the product information.[3][5]

What recurrence studies found

A TriNetX study reviewed records for 258,238 people with type 2 diabetes or obesity and a history of acute pancreatitis. In the subgroup without other recorded risk factors, recurrence was recorded in 13.8% of GLP-1 users and 40.9% of nonusers. Prescribing was not randomized, and the percentages apply to that subgroup.[1]

A separate retrospective cohort of 46,186 people with diabetes and either prior pancreatitis or elevated lipase found a higher hazard of pancreatitis with GLP-1 use (adjusted hazard ratio 1.252, 95% confidence interval 1.178 to 1.332). Only 10,933 people entered the cohort because of prior pancreatitis. The two studies used different populations and methods and cannot establish how a specific patient would respond.[6]

What older randomized trials can tell us

A 2017 meta-analysis found no statistically significant difference in pancreatitis in type 2 diabetes trials (odds ratio 0.93, 95% confidence interval 0.65 to 1.34). Of 113 eligible trials, 13 did not report pancreatitis and 72 reported no cases in any arm. The review did not estimate recurrence in people selected for a history of pancreatitis and predates tirzepatide trials. Its findings on gallbladder problems covered a separate outcome, gallstones.[2]

How chronic pancreatitis differs

In a study of people with chronic pancreatitis and without diabetes, researchers matched 1,422 patients per group. In the recurrence analysis, acute pancreatitis was recorded in 19 of 799 GLP-1 users (2.4%) and 76 of 704 comparison patients (10.8%). Mean follow-up was about 459 and 664 days, respectively. The authors could not verify the chronic pancreatitis diagnosis from clinical testing and cautioned against using these results to guide prescribing.[4]

If you had pancreatitis before, share when it happened, its known cause, and whether you have had more than one episode. That history helps your prescriber weigh the treatment options and decide how to follow up.

Frequently asked

Can you take semaglutide if you have had pancreatitis before?
Discuss the previous episode with your prescriber. Observational studies report different recurrence findings, and those results cannot establish whether semaglutide is appropriate for you.
What are the pancreatitis warning signs?
The Wegovy and Zepbound labels identify persistent or severe abdominal pain that may spread to the back, with or without nausea or vomiting. For symptoms suggestive of pancreatitis, stop treatment and seek medical care promptly.

Sources

  1. [1] Nassar M, Nassar O, Abosheaishaa H, Misra A (2024). Decreased risk of recurrent acute pancreatitis with semaglutide and tirzepatide in people with type 2 diabetes or obesity with a history of acute pancreatitis: A propensity matched global federated TriNetX database-based retrospective cohort study Diabetes & Metabolic Syndrome. PMID 39332263
  2. [2] Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, et al. (2017). Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials Diabetes, Obesity & Metabolism. PMID 28244632
  3. [3] Novo Nordisk (2026). WEGOVY (semaglutide) — prescribing information DailyMed, U.S. National Library of Medicine. Source
  4. [4] Dhali A, et al. (2026). Clinical Outcomes Associated with GLP-1 Receptor Agonist Exposure in Non-Diabetic Patients with Chronic Pancreatitis: A Retrospective Cohort Study Journal of Personalized Medicine. PMID 42645931
  5. [5] Eli Lilly and Company (2026). Zepbound (tirzepatide) prescribing information DailyMed, U.S. National Library of Medicine. Source
  6. [6] Calvarysky B, et al. (2026). Glucagon-Like Peptide-1 Analogues and the Risk of Recurrent Pancreatitis in Diabetic Patients With History of Pancreatitis or Elevated Lipase: Retrospective Cohort Analysis Diabetes/Metabolism Research and Reviews. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence